Concepedia

Author

Julia Dorn

Technical University of MunichORCID

Also Known As

Dirk Waldenmaier, Dorn, Julia, J Dorn, J. B. Dorn, J. Dorn, JULIA DORN, Julia Dorn

95

Publications

2.1K

Citations

26

H-Index

49

Concepts

All Affiliations

Technical University of MunichUniversity of TorontoMount Sinai HospitalKlinikum rechts der IsarNational and Kapodistrian University of Athens
JD

About

Julia Dorn is an author at Technical University of Munich specializing in medicine, pathology, and ovarian cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

16

584

2

Natural Sciences

2

2

51

3

Social Sciences

1

1

26

4

Anesthesia

1

1

26

5

Biochemistry

1

1

27

Julia Dorn

×

39

Publications

1.7K

Citations

23

H-Index

YearCitations

CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer

Holger Bronger, J. David Singer, Claudia Windmüller,

British Journal of Cancer

2016

257

A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients

Sherko Küemmel, Joerg Heil, Anna Rueland,

Annals of Surgery

2020

163

Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer.

George M. Yousef, Mary-Ellen Polymeris, Linda Grass,

PubMed

2003

133

Human kallikrein 8, a novel biomarker for ovarian carcinoma.

Tadaaki Kishi, Linda Grass, Antoninus Soosaipillai,

PubMed

2003

89

Proteome activity landscapes of tumor cell lines determine drug responses

Martin Frejno, Chen Meng, Benjamin Ruprecht,

Nature Communications

2020

83

Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker

Andreas Scorilas, Carla A. Borgoño, Nadia Harbeck,

Journal of Clinical Oncology

2004

78

MUTYH DNA glycosylase: the rationale for removing undamaged bases from the DNA

Enni Markkanen, Julia Dorn, Ulrich Hübscher

Frontiers in Genetics

2013

74

Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer

Carla A. Borgoño, Tadaaki Kishi, Andreas Scorilas,

Clinical Cancer Research

2006

64

tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression

Konstantina Panoutsopoulou, Tobias Dreyer, Julia Dorn,

Cancers

2021

55

Immunofluorometric Quantification of Human Kallikrein 5 Expression in Ovarian Cancer Cytosols and Its Association with Unfavorable Patient Prognosis

Eleftherios P. Diamandis, Carla A. Borgo ntilde o, Andreas Scorilas,

Tumor Biology

2003

53

Page 1